Invest with Confidence:
- Follow TipRanks' Top Wall Street Analysts to uncover their success rate and average return.
- Join thousands of data-driven investors – Build your Smart Portfolio for personalized insights.
Bicycle Therapeutics ( (BCYC) ) just unveiled an announcement.
Bicycle Therapeutics announced updated topline data from its Phase 1 trial of zelenectide pevedotin in combination with pembrolizumab, showing a 65% overall response rate in cisplatin-ineligible metastatic urothelial cancer patients. The company highlighted its strategic priorities for 2025, including advancing its radiopharmaceuticals pipeline and initiating multiple Phase 1/2 trials, supported by a strong financial position expected to last into the second half of 2027.
More about Bicycle Therapeutics
Bicycle Therapeutics is a clinical-stage pharmaceutical company that is developing a novel class of medicines called Bicycle® molecules, which are fully synthetic short peptides designed for high target binding affinity and selectivity. The company focuses on diseases underserved by existing therapeutics and is currently evaluating several candidates, including zelenectide pevedotin for Nectin-4 cancers.
YTD Price Performance: -7.31%
Average Trading Volume: 591,936
Technical Sentiment Consensus Rating: Buy
Current Market Cap: $918.6M
For a thorough assessment of BCYC stock, go to TipRanks’ Stock Analysis page.
